Binge Eating Disorder
Conditions
Brief summary
decrease of food craving in response to real food 3-7 days after treatment
Detailed description
decrease in fear of loss of control over eating and arousal/distress in response to real food, food craving in response to visual food cues, amount of food intake, trait level food craving 3-7 days after treatment and 1 month after treatment, decrease in number of days and episodes of binge eating and overeating 1 month after treatment, continuous decrease in food craving, fear of loss of control over eating and arousal/distress during intervention sessions
Interventions
DRUGFüllstoff DAC in hard gelatine capsules is used as placebo. Füllstoff DAC consists of mannitol 99.5 % and
colloidal Silicon Dioxide 0.5 %.
DRUGHydrocortison 10 mg JENAPHARM® Tabletten
Sponsors
Universitaetsmedizin Goettingen
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| decrease of food craving in response to real food 3-7 days after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| decrease in fear of loss of control over eating and arousal/distress in response to real food, food craving in response to visual food cues, amount of food intake, trait level food craving 3-7 days after treatment and 1 month after treatment, decrease in number of days and episodes of binge eating and overeating 1 month after treatment, continuous decrease in food craving, fear of loss of control over eating and arousal/distress during intervention sessions | — |
Countries
Germany
Outcome results
None listed